Dr. Falk Pharma GmbH vs Ellodi Pharmaceuticals LP - IPR2025-00056

Petitioner's Supplemental Mandatory Notice: Related Matters Section

General Order: Related Matters Updates

Patent Owner's Updated Mandatory Notices

Patent Owner's Notice of Intent to Designate I. Agarwal as Backup Counsel

Patent Owner's Updated Exhibit List

Agarwal Declaration

Joint Stipulation to Modify Due Dates 1-3

Patent Owner's Notice of Deposition of Alan F. Parr, Pharm.D., Ph.D.

Patent Owner's Objections Pursuant to 37 CFR 42.64(b)(1)

Institution Decision: DECISION Granting Institution of Inter Partes Review 35 U.S.C. § 314

Order: SCHEDULING ORDER

Patent Owner's SurReply

Petitioner’s Reply to Patent Owner’s Preliminary Response

E-mail authorizing briefing

Declaration of Martyn Christopher Davies

Merriam-Webster's Collegiate Dictionary, 11th ed. (2006)

Curriculum vitae of Martyn Christopher Davies

Patent Ower's Preliminary Response

Petitioner’s Supplemental Mandatory Notice: Related Matters Section

Notice: Notice filing date accorded

Notice : Mandatory Notice

Notice : Power of Attorney

U.S. Patent No. 11,260,061 to Gosselin et al.

U.S. Publication No. 20070111978 to Dohil et al. (“Dohil”)

“Guidance for Industry: Orally Disintegrating Tablets”

Notice of Publication of FDA Guidance for Industry on Orally Disintegrating

Svoboda et al., “Oral formulations of budesonide: a novel treatment for inf

Tan et al., “Eosinophilic gastroenteritis treated with non-enteric-coated b

Kolkman et al., “Evaluation of oral budesonide in the treatment of active d

Siewert et al., “Eosinophilic gastroenteritis with severe protein-losing

Elsing et al., “Budesonide for the treatment of obstructive eosinophilic

Aceves et al., “Topical viscous budesonide suspension for treatment of

Aceves et al., “Oral Viscous Budesonide: A potential new therapy for

The United States Pharmacopeia, USP 32, 2009 at pages 262-263 “<701>

Danckwerts, “Intraoral Drug Delivery: A Comparative Review,” American

Fu et al., “Orally fast disintegrating tablets: developments, technologies

Shukla et al., “Mouth Dissolving Tablets I: An overview of formulation tech

U.S. Publication No. 20050232988 to Venkatesh et al.

Goodman & Gilman’s: The Pharmacological Basis of Therapeutics, 11th

Budenofalk® Brochure (2005)

Budenofalk® Advertisement (2007)

Curriculum Vitae of Alan F. Parr, Pharm.D., Ph.D.

Conway, “Solid dosage forms,” Chapter 4.1 in Pharmaceutical Manufacturing

Wen, “Adsorption at solid surfaces: pharmaceutical applications,”

Physical Pharmacy: Physical Chemical Principles in the Pharmaceutical

Prosecution history excerpts from U.S. Application No. 17/211,119, which

U.S. Publication No. 2011/0081411 to Perrett et al.

U.S. Publication No. 2009/0191275 to Dohil et al. (“Dohil2009”)

Redline comparison of Dohil and Dohil2009

McGraw-Hill Dictionary of Scientific and Technical Terms, Sixth Edition

EP3041476B1

The Opposition Division of the European Patent Office decision regarding

International Publication No. WO2011041509

Roeder et al., “Safety and efficacy of fluticasone propionate in the

Remedios et al., “Eosinophilic esophagitis in adults: clinical, endoscopic

Konikoff et al., “A randomized, double-blind, placebo-controlled trial of f

Khan et al., “An approach for rapid disintegrating tablet: a review,” Int’l

Prosecution history excerpts from U.S. Application No. 14/917,125, which

“Cellulose, Silicified Microcrystalline,” Handbook of Pharmaceutical

Declaration of Alan F. Parr, Pharm.D., Ph.D. regarding U.S. 11,260,061

Dr. Falk Pharma Brochure (2008)

Petition : as filed

Notice : Power of Attorney